Home › Funds › Royce & Associates › SUPN
Royce & Associates position in SUPN
SUPERNUS PHARMACEUTICALS · Health Care
Latest position (Q2 2026)39.52K sh
Reported value held$1.84M
Portfolio Weight0.01%
First reportedQ3 2021
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 371.32K | $9.90M | New |
| Q4 2021 | 258.12K | $7.53M | Reduce |
| Q1 2022 | 53.81K | $1.74M | Reduce |
| Q2 2022 | 44.89K | $1.30M | Reduce |
| Q3 2022 | 44.73K | $1.51M | Hold |
| Q4 2022 | 43.80K | $1.56K | Reduce |
| Q1 2023 | 43.62K | $1.58K | Hold |
| Q3 2023 | 18.75K | $516.94K | New |
| Q4 2024 | 12.94K | $467.84K | New |
| Q1 2025 | 24.58K | $805.06K | Add |
| Q2 2025 | 32.50K | $1.02M | Add |
| Q3 2025 | 40.77K | $1.95M | Add |
| Q4 2025 | 197.74K | $9.83M | Add |
| Q1 2026 | 229.94K | $11.89M | Add |
| Q2 2026 | 39.52K | $1.84M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding SUPN
- BlackRock Inc 9.35M sh · $434.87M · Q2 2026
- Vanguard Group 6.05M sh · $300.61M · Q4 2025
- Millennium Management 3.85M sh · $179.21M · Q2 2026
- Geode Capital Management 1.57M sh · $73.04M · Q2 2026
- Renaissance Technologies 1.48M sh · $68.75M · Q2 2026
- Citadel Advisors 1.42M sh · $66.02M · Q2 2026
- Two Sigma Investments 1.18M sh · $55.09M · Q2 2026
- Morgan Stanley 876.84K sh · $40.78M · Q2 2026
- Goldman Sachs Group 819.43K sh · $38.11M · Q2 2026
- D. E. Shaw & Co 767.67K sh · $35.70M · Q2 2026
- Northern Trust Corp 733.37K sh · $34.11M · Q2 2026
- Charles Schwab Investment Management 703.55K sh · $32.72M · Q2 2026